When was InSphero founded?

InSphero was founded in 2009 and raised its 1st funding round within a year of its incorporation.

Where is InSphero located?

InSphero is headquartered in Schlieren, Switzerland.

How many employees does InSphero have?

As of Sep 30, 2026, the latest employee count at InSphero is 82.

Is InSphero a funded company?

InSphero is a funded company, having raised a total of $35M across 10 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2009.

When was the latest funding round of InSphero?

InSphero's latest funding was a $***** Series D round on Mar 31, 2023, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In Switzerland, the Life Sciences Platforms and Tools sector has seen $42.4M in funding in 2026 to date.

Where does InSphero rank among its competitors?

InSphero ranks 8th amongst 535 active competitors, of which 171 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Pandorum, which secured $429K in Mar, 2026.

Who are the top competitors of InSphero?

InSphero's top competitors include MedGenome, Aspen Neuroscience and Biocytogen. Among them, Pandorum secured the most recent funding round in March, 2026.

InSphero - 2026 Company Profile, Funding & Competitors

InSphero is a series D company based in Schlieren (Switzerland), founded in 2009. It operates as a Developer of cell based assays for drug screening. InSphero has raised $35M in funding from investors like Redalpine, ZEISS and Venturelab. The company has 535 active competitors, including 171 funded and 85 that have exited. Its top competitors include companies like MedGenome, Aspen Neuroscience and Biocytogen.

Company Details

Developer of cell-based assays for drug screening. The organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell invasion assays, cell-to-cell interaction, cell-to-extracellular matrix interaction services. The company is focused on providing assays for metabolic diseases, oncology, and liver diseases.

Website: insphero.com
Social
Email ID: *****@insphero.com
Phone Number: +1 **********

Key Metrics

Founded Year

2009

Location

Schlieren, Switzerland

Stage

Series D

Total Funding

$35M in 10 rounds

Latest Funding Round

Series D, Mar 31, 2023, $*****

Investors

Redalpine & 9 more

Ranked

8^th among 535 active competitors

Employee Count

82 as on Sep 30, 2026

Investment & Acquisitions

PhenoVista

Similar Companies

Pandorum & 79 more

View InSphero's full profile

InSphero has raised a total funding of $35M over 10 rounds. Its first funding round was on 2009. Its latest funding round was a Series D round on Mar 31, 2023 for $*****. 1 investor participated in its latest round. InSphero has 9 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of InSphero:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 31, 2023	4102181	Series D	2129017	8646652	1327802	6215703
Jun 30, 2020	7489777	Grant (prize money)	2399634	4369889	1960421	EIC Fund
Jan 01, 2020	9314904	Grant (prize money)	4998419	3869397	1715176	Europa

Access funding benchmarks and valuations. Sign up today!

View details of InSphero's funding rounds and investors

InSphero's employee count trend

InSphero has 82 employees as of Sep 26. Here is InSphero's employee count trend over the years:

Uncover InSphero's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of InSphero include MedGenome, Aspen Neuroscience and Biocytogen. Here is the list of Top 10 competitors of InSphero, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Aspen Neuroscience 2018, San Diego (United States), Public	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Revelation Partners, Orbimed & 22 others	69/100
3rd	Biocytogen 2008, Wakefield (United States), Public	Provider of integrated solutions for next-generation antibody drug development	$301M	CMB International Capital, SDIC & 12 others	69/100
4th	Personalis 2011, Menlo Park (United States), Acquired	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	68/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	67/100
6th	Applied StemCell 2008, Milpitas (United States), Acquired	Provider of animal and cell line models as tools for drug discovery and diagnostics	$67.5M	Fosun, Advantech Capital & 8 others	66/100
7th	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$52.1M	IAN Group, BTB Venture & 87 others	65/100
8th	InSphero 2009, Schlieren (Switzerland), Series D	Developer of cell based assays for drug screening	$35M	EIC Fund, Zurcher Kantonalbank & 8 others	64/100
9th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	64/100
10th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	63/100